Enrico Montefusco - Concepedia

Author

Enrico Montefusco

Sapienza University of Rome

Also Known As

Carlo-Stella, C., E Montefusco, E. Montefusco, Enrico Montefusco, Montefusco, Enrico, Paolo de Fabritiis

145

Publications

Citations

H-Index

Concepts

All Affiliations

Sapienza University of Rome University of Rome Tor Vergata University of Bologna St. Eugenio Hospital Ospedale di Belcolle

About

Enrico Montefusco is an author at Sapienza University of Rome specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	25	860
2	Health Sciences	6	6	176
3	Public Health	2	2	110
4	Cell Biology	2	2	62
5	Classical Hematology	2	2	109

Enrico Montefusco

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration Giuliana Alimena, Enrica Morra, Mario Lazzarino, Blood	1988	180
A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia Michele Baccarani, Gianantonio Rosti, Antonio De Vivo, Blood	2002	167
Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma Maria Christina Cox, Italo Nofroni, Luigi Ruco, Leukemia & lymphoma/Leukemia and lymphoma Hematological MalignancyLymphoid NeoplasiaEvent Free SurvivalMedicineMalignant Blood Disorder	2008	107
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party Gabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, Blood	2011	106
Differences among young adults, adults and elderly chronic myeloid leukemia patients Fabio Castagnetti, Gabriele Gugliotta, Michele Baccarani, Annals of Oncology Hematological MalignancyFamily MedicineYoung AdultsAgingHealth Policy	2014	97
Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients Ilaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, Clinical Cancer Research	2006	95
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP Michele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, Blood Advances Mixed-phenotype Acute LeukemiaPathologyCell Replacement TherapyLogistic AnalysisMyeloid Neoplasia	2019	89
Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Giulia Greco, Doriana Fruci, Daniele Accapezzato, PubMed	1996	88
Melphalan treatment in patients with myelofibrosis with myeloid metaplasia Maria Concetta Petti, Roberto Latagliata, Teresa Spadea, British Journal of Haematology	2002	87
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis Syed K. Hasan, Ashley N. Mays, Tiziana Ottone, Blood	2008	81

Page 1